Concepedia

INFLUENCE OF ERYTHROMYCIN ON THE PHARMACOKINETICS OF XIMELAGATRAN MAY INVOLVE INHIBITION OF P-GLYCOPROTEIN-MEDIATED EXCRETION

Ulf G. Eriksson, Hassan Dorani, Johan Karlsson, Holger Fritsch, Kurt‐Jürgen Hoffmann, Lis Olsson, Troy C. Sarich, Ulrika Wall, Kajs-Marie Schützer

Drug Metabolism and Disposition · 2006 · 43 citations · 20 references

DOI

Concepts

References

20

Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial

S. Bertil Olsson · The Lancet · 2003 · 811 citations

, , +15

Interrelationship Between Substrates and Inhibitors of Human CYP3A and P-Glycoprotein

Richard B. Kirn, Christoph Wandel, Brenda F. Leake et al. · Pharmaceutical Research · 1999 · 460 citations

, , +10

Secondary Prevention of Venous Thromboembolism with the Oral Direct Thrombin Inhibitor Ximelagatran

Sam Schulman, Karin Wåhlander, Torbjörn Lundström et al. · New England Journal of Medicine · 2003 · 457 citations · Full text

, , +14

Oral ximelagatran for secondary prophylaxis after myocardial infarction: the ESTEEM randomised controlled trial

Lars Wallentin, Robert G. Wilcox, W Douglas Weaver et al. · The Lancet · 2003 · 369 citations

, , +16

Comparison of Ximelagatran with Warfarin for the Prevention of Venous Thromboembolism after Total Knee Replacement

Charles W. Francis, Scott D. Berkowitz, Philip C. Comp et al. · New England Journal of Medicine · 2003 · 319 citations

, , +13